Y Intercept Hong Kong Ltd Increases Position in Xeris Biopharma Holdings, Inc. $XERS

Y Intercept Hong Kong Ltd lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 78.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 161,793 shares of the company’s stock after buying an additional 71,148 shares during the period. Y Intercept Hong Kong Ltd owned approximately 0.09% of Xeris Biopharma worth $938,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in XERS. Royal Bank of Canada increased its position in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after acquiring an additional 3,594 shares during the last quarter. Millennium Management LLC lifted its position in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after acquiring an additional 369,420 shares during the period. Goldman Sachs Group Inc. lifted its position in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after acquiring an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP purchased a new position in shares of Xeris Biopharma in the 1st quarter valued at approximately $170,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $8.34 on Monday. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The stock has a fifty day moving average of $6.86 and a two-hundred day moving average of $6.68. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 139.00 and a beta of 0.62. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.87 and a fifty-two week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, Director Dawn Halkuff sold 20,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $121,800.00. Following the transaction, the director directly owned 95,000 shares in the company, valued at approximately $578,550. This represents a 17.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00. Following the sale, the insider directly owned 1,691,126 shares in the company, valued at $13,579,741.78. This represents a 5.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 251,500 shares of company stock worth $1,846,457 in the last ninety days. Company insiders own 4.35% of the company’s stock.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.